Celldex drug stumbles in eczema; Epigenetic editing startup cuts staff

Celldex Therapeutics will halt development of barzolvolimab for eczema after Phase 2 trial failure, but plans approval filing for chronic hives. NChroma Bio will cut staff and explore strategic alternatives after halting hepatitis B drug testing. Isomorphic Labs partners with Merck for cancer drug development. Teva Pharmaceuticals' R&D chief is leaving, but analysts remain confident. VitriVax raised $87M for Lyme disease vaccine development.

Original reporting
Published Nov 20, 2026, 1:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 20, 2026, 2:45 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Celldex drug stumbles in eczema; Epigenetic editing startup cuts staff — source image
Decision brief

The 30-second read

$CLDXBearishMed
01

Why it matters

Collectively, the disclosures shift probability-weighting across multiple pipeline assets: eczema development is being stopped, hepatitis B testing is paused pending strategic review, while new partnered oncology work and new vaccine funding improve forward optionality for other programs.

02

Market read

Traders can reassess near-term pipeline risk for CLDX and NCHM, while factoring financing and partnership catalysts for VITR and ISOM/MRK, and managing transition risk for TEVA.

03

What to watch

For nChroma, strategic alternatives could lead to asset sale or partnership that changes risk quickly; for Isomorphic-Merck, the lack of disclosed targets and economics may delay meaningful repricing until more scientific and financial details emerge.

Relevance 7/10Novelty 6/10Timing: today, after-hours/next-session positioning around clinical-development and financing headlines

Background

The article is a multi-company biotech roundup covering Celldex’s eczema Phase 2 setback, nChroma’s hepatitis B program halt and restructuring, an Isomorphic-Merck oncology collaboration, a Teva executive departure, and VitriVax’s Series C financing for a Lyme vaccine.

Company-level read

Ticker impact

$CLDXBearishHigh confidence
Context

Celldex will stop developing barzolvolimab in eczema after Phase 2 results failed to meet its internal hurdle rate for continued development.

Expected impact

Likely downward pressure as investors reprice the eczema franchise and reduce probability-weighted value from barzolvolimab in that market.

Evidence & confidence

The article states a development stop in eczema based on Phase 2 underperformance versus an internal hurdle, which is a direct risk reduction for that indication.

$MRKNeutralLow confidence
Context

Merck is named as the partner in Isomorphic Labs' new cancer collaboration, covering development costs for resulting small-molecule programs.

Expected impact

Neutral to slightly positive, with investors focusing on whether the collaboration meaningfully expands Merck's oncology pipeline.

Evidence & confidence

The article does not disclose program targets, milestones, or expected economics for Merck, making directional impact uncertain.

$TEVANeutralMedium confidence
Context

Teva's R&D chief and chief medical officer Eric Hughes is leaving, with David Gardiner temporarily covering the role until a permanent successor is named.

Expected impact

Likely limited market impact unless investors interpret the exit as signaling internal issues; otherwise, shares may stabilize on continuity.

Evidence & confidence

The article highlights a surprise leadership change but includes analyst support and does not cite operational failures or guidance changes.

Market effects

Biopharma sentiment may tilt toward higher selectivity in immunology and hepatitis B development, while oncology partnerships and vaccine financing remain supportive signals.

Primarily US-listed biotech sentiment; limited direct cross-asset impact expected.

Oncology collaboration and vaccine development are globally relevant, but the article provides no cross-border regulatory or pricing details.

Counterpoint

Analysts may argue eczema Phase 2 failures are not decisive for barzolvolimab’s broader platform, especially given planned chronic hives filing and prior late-stage success.

Key entities

  • Celldex Therapeutics

    Stops barzolvolimab eczema development after Phase 2 underperformance versus internal hurdle rate.

  • nChroma Bio

    Halts hepatitis B lead program and evaluates strategic alternatives amid staff cuts and restructuring.

  • Isomorphic Labs

    Announces a cancer-focused small-molecule collaboration with Merck with milestones and royalties.

  • Merck & Co.

    Partner covering development costs for programs arising from the Isomorphic collaboration.

  • Teva Pharmaceutical

    R&D chief and CMO Eric Hughes exits; David Gardiner temporarily covers the role.

Related articles

$TEVALow

Teva Settles Generic Drug Price-Fixing Case With 45 States

Teva Pharmaceutical Industries reached a preliminary settlement agreement with 45 states, Washington, D.C., and two U.S. territories over allegations of generic drug price-fixing. The terms, affected drugs, and pricing conditions are undisclosed. Teva faces claims of conspiring to inflate prices on 112 generic drugs, with some price hikes exceeding 1,000%. The case is ongoing, and no final agreement has been reached.

$LLYMedAI 8/10

Rx Rundown: Ollin Biosciences, AstraZeneca, Isomorphic Labs and more

Eli Lilly, AbbVie, Johnson & Johnson, and others announced major deals and acquisitions in the biopharma sector, totaling billions. AstraZeneca, Roche, and Novo Nordisk received FDA approvals for new treatments. Isomorphic Labs raised $5 billion in private financing. AstraZeneca cut 600 jobs, while Cellectis plans to cut 70% of its workforce.

$MRKHigh

Merck Announces TroFuse-015 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoint of Overall Survival (OS) in Third-Line or Later Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma

Merck (MRK) announced that its Phase 3 TroFuse-015 trial of sacituzumab tirumotecan (Sac-TMT) met the primary endpoint of overall survival in patients with advanced gastroesophageal adenocarcinoma. Sac-TMT, licensed from Kelun-Biotech, showed a statistically significant improvement in OS compared to treatment of physician’s choice. The trial is part of Merck's broader TroFuse program evaluating Sac-TMT across multiple tumor types.